Albalawi, F.S.; Bhat, M.A.; Bakheit, A.H.; Rahman, A.F.M.M.; Alsaif, N.A.; Jones, A.M.; Romero-Canelon, I.
Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors. Pharmaceuticals 2025, 18, 1051.
https://doi.org/10.3390/ph18071051
AMA Style
Albalawi FS, Bhat MA, Bakheit AH, Rahman AFMM, Alsaif NA, Jones AM, Romero-Canelon I.
Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors. Pharmaceuticals. 2025; 18(7):1051.
https://doi.org/10.3390/ph18071051
Chicago/Turabian Style
Albalawi, Fatemah S., Mashooq A. Bhat, Ahmed H. Bakheit, A. F. M. Motiur Rahman, Nawaf A. Alsaif, Alan M. Jones, and Isolda Romero-Canelon.
2025. "Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors" Pharmaceuticals 18, no. 7: 1051.
https://doi.org/10.3390/ph18071051
APA Style
Albalawi, F. S., Bhat, M. A., Bakheit, A. H., Rahman, A. F. M. M., Alsaif, N. A., Jones, A. M., & Romero-Canelon, I.
(2025). Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors. Pharmaceuticals, 18(7), 1051.
https://doi.org/10.3390/ph18071051